Promising early results from novel cancer immunotherapies have been behind the some of the most meteoric share price increases of 2024 so far.
An analysis of stock movements from Evaluate Pharma’s database shows that five of the top-10 share price increases in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?